Abstract
Background Despite rising rates of vaccination, quarantine remains critical to control SARS-CoV-2 transmission. COVID-19 quarantine length around the world varies in part due to the limited amount of empirical data.
Objective To assess post-quarantine transmission risk for various quarantine lengths.
Design Cohort study.
Setting Four US universities, September 2020 to February 2021.
Participants 3,641 students and staff were identified as close contacts to SARS-CoV-2-positive individuals. They entered strict or non-strict quarantine and were tested on average twice per week for SARS-CoV-2. Strict quarantine included designated housing with a private room, private bathroom and meal delivery. Non-strict quarantine potentially included interactions with household members.
Measurements Dates of exposure and last negative and first positive tests during quarantine.
Results Of the 418 quarantined individuals who eventually converted to positive, 11%, 4.2%, and 1.2% were negative and asymptomatic on days 7, 10 and 14, respectively. The US CDC recently shortened its quarantine guidance from 14 to 7 days based on estimates of 2.3-8.6% post-quarantine transmission risk at day 7, significantly below the 11% risk we report here. Notably, 6% of individuals tested positive after day 7 in strict quarantine, versus 14% in non-strict quarantine. Ongoing exposure during quarantine likely explains the higher rate of COVID-19 in non-strict quarantine.
Limitations Quarantine should be longer for individuals using antigen testing, given antigen testing’s lower sensitivity than qPCR. Results apply in settings in which SAR-CoV-2 variants do not affect latent period.
Conclusions To maintain the 5% transmission risk that the CDC used in its guidance, our data suggest that quarantine with qPCR testing 1 day before intended release should extend to 10 days for non-strict quarantine.
Funding Source None.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We have no funding source to report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Our research protocol was approved by the IRB of the Harvard Faculty of Medicine (IRB20-0581), and we have data use agreements with Boston University, Duke University (DUA21-0149) and Northeastern University (DUA20-1481).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Co-senior authors
Data Availability
Individual-level data not available due to privacy restrictions. Aggregated data available upon request.
